首頁
瀏覽量: 229
- 產(chǎn)品名稱： DXD
- 產(chǎn)品貨號(hào)： CS00056
- 貨期： 現(xiàn)貨
- 價(jià)格與訂購(gòu)： 1390
- 數(shù)量：
庫(kù)存： 10
- 規(guī)格： 1mg
- 產(chǎn)品信息
- 如何訂購(gòu)
產(chǎn)品描述
Dxd is a potent inhibitor of DNA topoisomerase I with an IC50 of 0.31 μM. It is used as a conjugated drug of HER2-targeting ADC.
靶點(diǎn)活性
Topoisomerase I Camptothecins
體外活性
Dxd shows obviously suppression on the HER2-positive KPL-4, NCI-N87, and SK-BR-3 cell lines with IC50s of 26.8, 25.4, and 6.7 ng/mL respectively, but with no such inhibition on MDA-MB-468 (IC50, >10,000 ng/mL)[1].
體內(nèi)活性
Dxd is cytotoxic to human cancer cell lines of KPL-4, NCI-N87, SK-BR-3, and MDA-MB-468 with IC50s of 1.43 nM-4.07 nM. In HER2 low-expressing ST565 and ST313 models has HER2 IHC 1+/FISH-negative expression[1].
別名
Exatecan derivative for ADC , 化合物Dxd
純度
98%
分子量
493.48
分子式
C26H24FN3O6
CAS No.
1599440-33-1
存儲(chǔ)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
溶解度
DMSO: 50 mg/mL (101.32 mM)
H2O: insoluble
( < 1 mg/ml refers to the product slightly soluble or insoluble )
參考文獻(xiàn)
1. Ogitani Y, et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res. 2016 Oct 15;22(20):5097-5108.
Note
For research use only .
上一篇 MC-Val-Cit-PAB
sulfo-SPDB 下一篇
地 址：
產(chǎn)品銷售：
E - mail ：
郵 編：
Amily
